Session 7: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided all RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Doublet Chemo + Panitumumab

Friday, March 31, 2023

8:15 AM – 8:30 AM ET

Presenter(s)

Smitha Krishnamurthi, MD

Department of Hematology and Oncology at Cleveland Clinic